Rapid antigen test

Chinese IVD Industry Report 2022-2027: Trends, Growth, Shares, Impact of COVID-19, Company Analyses - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 24, 2022

The "China in Vitro Diagnostics Market, Size, Forecast 2022-2027, Industry Trends, Growth, Share, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China in Vitro Diagnostics Market, Size, Forecast 2022-2027, Industry Trends, Growth, Share, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The Chinese In-vitro diagnostics (IVD) Market is central to the provision of healthcare globally, and is estimated to be US$ 18.9 billion in 2027.
  • Remarkably, over the past years, the rate of Chinese economic growth has been impressive, setting lucrative growth in GDP per year.
  • In addition, the Chinese IVD landscape has historically been controlled by large international providers, with few domestic instrumentation and assay suppliers.

iXensor Confirms PixoTest® COVID-19 Antigen Test Detects Omicron and Other Key Variants of Concern

Retrieved on: 
Wednesday, December 22, 2021
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211222005223/en/
    iXensor's PixoTest COVID-19 Antigen Test effectively detects Omicron and other key variants of concern (Photo: Business Wire)
    iXensor, the pioneer of mobile health, declares that its computer vision-powered PixoTest COVID-19 Antigen Test effectively detects all major SARS-CoV-2 variants including Omicron (B.1.1.529) after completing two validation studies.
  • The in-silico study evaluated the amino acid sequences of N protein wild type and the Omicron variant (P13L, E31del, R32del, S33del, R203K, G204R), concluding that Omicron is detectable by PixoTest COVID-19 Antigen Test.
  • Most importantly, the sensitivity of PixoTest COVID-19 Antigen Test is not affected by the Omicron and other Variants of Concern.
  • In 2017, iXensor introduced the PixoTest Blood Glucose Monitoring System as the world's first US FDA-approved smartphone camera-based blood test.

Great Success for the 4th Edition of the Filming Italy Sardegna Festival Held at Forte Village

Retrieved on: 
Friday, July 30, 2021

MILAN, Italy, July 30, 2021 (GLOBE NEWSWIRE) -- The fourth edition of the Filming Italy Sardegna Festival, conceived and directed by Tiziana Rocca, has come to a close.

Key Points: 
  • MILAN, Italy, July 30, 2021 (GLOBE NEWSWIRE) -- The fourth edition of the Filming Italy Sardegna Festival, conceived and directed by Tiziana Rocca, has come to a close.
  • Supported by the Region of Sardinia, the festival took place from 21 - 25 July at Forte Village.
  • Once again it distinguished itself as an exclusive event that saw Italian and international stars of exceptional fame walk the stage.
  • As with last year, the Filming Italy Sardegna Festival has also been made possible thanks to the extraordinary Covid Protection Protocol which has seen all the stars undergo Antigen tests and, where necessary, PCR tests too to ensure a safe festival.

Qorvo Biotechnologies Omnia™ SARS-CoV-2 Antigen Test Platform Validated in National Institutes of Health (NIH) Funded Study

Retrieved on: 
Wednesday, July 28, 2021

Atlantas Center for Microsystems Engineered Point-of-Care Technologies (ACME-POCT) completed two independent studies, an adult study and a pediatric study, verifying the low SARS-CoV-2 limit of detection (LOD) and high specificity/sensitivity of the Qorvo Omnia Antigen Test.

Key Points: 
  • Atlantas Center for Microsystems Engineered Point-of-Care Technologies (ACME-POCT) completed two independent studies, an adult study and a pediatric study, verifying the low SARS-CoV-2 limit of detection (LOD) and high specificity/sensitivity of the Qorvo Omnia Antigen Test.
  • Three pediatric samples that tested negative on the Qorvo Omnia Antigen Test had Cycle threshold (Ct) values greater than 38 on the Hologic system, indicating very low viral loads in those samples.
  • Overall, the investigators found the Qorvo Omnia platform design intuitive and easy to use while producing rapid test results compared to high-sensitivity molecular testing systems, with test results within 20 minutes from sample collection.
  • This project has been funded in part by the NIH Rapid Acceleration of Diagnostics (RADxSM) initiative with federal funds from the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health.

Global WholeHealth Partners Corp.'s (OTC: GWHP) Antibody IgG/IgM and Antigen Tests That They Offer Are Capable of Detecting the DELTA B.1.617.2, United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) of COVID 19 SARS 2

Retrieved on: 
Monday, July 26, 2021

Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM and Antigen tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses.

Key Points: 
  • Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM and Antigen tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses.
  • The government is working with the diagnostics industry to ensure the gains in domestic manufacturing are not lost over time.
  • To conquer COVID and win this war, Global must keep up the research and development of tests.
  • Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID.

CityHealth Launches RapidReturn COVID-19 Travel Kit

Retrieved on: 
Monday, July 26, 2021

The RapidReturn Kit allows US-bound travelers to take a supervised Rapid Antigen test and receive travel-approved results from anywhere in the world.

Key Points: 
  • The RapidReturn Kit allows US-bound travelers to take a supervised Rapid Antigen test and receive travel-approved results from anywhere in the world.
  • Priced at just $75 per kit, each kit contains 2 tests.
  • One kit per traveler is recommended, so travelers are prepared for flight delays or inconclusive results that require a second test.
  • CityHealth's RapidReturn Kit is one of the most affordable and user-friendly pre-travel COVID test kits on the market.

Covid-19 Tests Innovations Drawing New Interest from FDA and Consortiums

Retrieved on: 
Thursday, July 22, 2021

For many establishments, the tests help to assess levels of risk for patrons, employees and other interested parties.

Key Points: 
  • For many establishments, the tests help to assess levels of risk for patrons, employees and other interested parties.
  • Now the FDA has released guidance to BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV) for its T-cell immune response diagnostic platform CoviDTH to begin Phase I/II Clinicial Trials.
  • However, later in July, Abbott was reported to be working to import the PanBio Covid-19 self tests from Korea.
  • The Sofia test was the first rapid antigen test to get an FDA greenlight , back in May of last year.

Covid-19 Tests Innovations Drawing New Interest from FDA and Consortiums

Retrieved on: 
Thursday, July 22, 2021

VANCOUVER, B.C., July 22, 2021 /PRNewswire/ -- USA News Group  -  Two of the world's most prominent billionaires, George Soros and Bill Gates, recently made headlines backing a consortium to buy UK Covid-19 test maker Mologic for $41 million ahead of a new initiative of a global rollout for rapid result testing. As demand shifts, newer innovations from not only from Mologic are gaining attention, including a new T-Cell Immune Response diagnostic from BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV), antigen tests from Abbott Laboratories (NYSE: ABT), Chembio Diagnostics, Inc. (NASDAQ: CEMI) and Quidel Corporation (NASDAQ: QDEL), and antibody tests from Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX).

Key Points: 
  • For many establishments, the tests help to assess levels of risk for patrons, employees and other interested parties.
  • Now the FDA has released guidance to BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV) for its T-cell immune response diagnostic platform CoviDTH to begin Phase I/II Clinicial Trials.
  • However, later in July, Abbott was reported to be working to import the PanBio Covid-19 self tests from Korea.
  • The Sofia test was the first rapid antigen test to get an FDA greenlight , back in May of last year.

Chembio Diagnostics Receives $28.3 Million Purchase Order from Bio-Manguinhos for DPP SARS-CoV-2 Antigen Tests in Brazil

Retrieved on: 
Wednesday, July 21, 2021

HAUPPAUGE, N.Y., July 20, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, announced its receipt today of a $28.3 million purchase order from Bio-Manguinhos for the purchase of Chembio’s DPP SARS-CoV-2 Antigen tests for delivery during 2021 to support the urgent needs of Brazil’s Ministry of Health in addressing the COVID-19 pandemic. The DPP SARS-CoV-2 Antigen test is designed to detect the SARS-CoV-2 antigen, which indicates an active COVID-19 infection, in only 20 minutes using a minimally invasive nasal swab. Chembio’s delivery of the full number of tests covered by the purchase order may be affected by limitations of Chembio’s supply chain, staffing, and liquidity, and other matters outside Chembio’s control.

Key Points: 
  • The DPP SARS-CoV-2 Antigen test is designed to detect the SARS-CoV-2 antigen, which indicates an active COVID-19 infection, in only 20 minutes using a minimally invasive nasal swab.
  • Chembio has a long-standing relationship with Bio-Manguinhos, having supplied multiple products for point-of-care detection of COVID-19 antibodies, HIV, and other infectious diseases.
  • We believe the purchase order validates the investments we made earlier this year in inventory for the DPP SARS-CoV-2 Antigen test and look forward to ramping up production.
  • Chembios portfolio of DPP-based point-of-care tests with FDA regulatory approvals include the DPP HIV-Syphilis System (PMA approved), DPP HIV 1/2 Assay (PMA approved and CLIA waived), DPP Zika IgM System (510(k)), and DPP Ebola Antigen System (EUA).

State of Delaware Selects Quidel for COVID-19 Testing Program at Schools

Retrieved on: 
Monday, July 19, 2021

Quidel Corporation (NASDAQ: QDEL) (Quidel), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it is entering a partnership with the State of Delaware to implement a full-service, turn-key COVID-19 testing program to support the reopening of K-12 schools in the fall through its new service provider, Quidel Services, LLC.

Key Points: 
  • Quidel Corporation (NASDAQ: QDEL) (Quidel), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it is entering a partnership with the State of Delaware to implement a full-service, turn-key COVID-19 testing program to support the reopening of K-12 schools in the fall through its new service provider, Quidel Services, LLC.
  • Students and faculty that opt-in to the COVID-19 screening program will be tested with Quidels rapid antigen tests.
  • DPH and Delawares Department of Education will launch the initiative at five pilot schools for summer school enrollees.
  • Quidel can expand the program to all of the States K-12 schools when classrooms fully reopen for the fall semester.